North China Pharmaceutical Co (SHSE:600812) Cyclically Adjusted FCF per Share: ¥0.11 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600812 North China Pharmaceutical Co Ltd SHSE:600812
52 GF Score
Price ¥5.08
GF Value ¥4.85
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is North China Pharmaceutical Co Cyclically Adjusted FCF per Share?

North China Pharmaceutical Co SHSE:600812 +1.40% 52 Cyclically Adjusted FCF per Share is ¥0.11 as of Mar. 2026. GuruFocus rates SHSE:600812 with a GF Score™ of 52/100 and a GF Value™ of ¥4.85 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

North China Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was ¥0.021. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥0.11 for the trailing ten years ended in Mar. 2026.

During the past 12 months, North China Pharmaceutical Co's average Cyclically Adjusted FCF Growth Rate was 120.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of North China Pharmaceutical Co was 47.70% per year. The lowest was -45.50% per year. And the median was -29.25% per year.

As of today (2026-08-13), North China Pharmaceutical Co's current stock price is ¥5.08. North China Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ¥0.11. North China Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is 46.18.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of North China Pharmaceutical Co was 166.50. The lowest was 38.18. And the median was 89.33.


North China Pharmaceutical Co  (SHSE:600812) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

North China Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=5.08/0.11
=46.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of North China Pharmaceutical Co was 166.50. The lowest was 38.18. And the median was 89.33.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


North China Pharmaceutical Co Cyclically Adjusted FCF per Share Related Terms


North China Pharmaceutical Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for North China Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

North China Pharmaceutical Co Cyclically Adjusted FCF per Share Chart

North China Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 -0.08 0.00 0.04 0.10

North China Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.08 0.10 0.11

SHSE:600812 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, North China Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


North China Pharmaceutical Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, North China Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where North China Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.


SHSE:600812
52GF Score
North China Pharmaceutical Co Ltd SHSE:600812
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

North China Pharmaceutical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, North China Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.021/116.3033*116.3033
=0.021

Current CPI (Mar. 2026) = 116.3033.

North China Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.228 101.400 -0.262
201609 -0.098 102.400 -0.111
201612 -0.066 102.600 -0.075
201703 -0.037 103.200 -0.042
201706 -0.037 103.100 -0.042
201709 -0.032 104.100 -0.036
201712 0.045 104.500 0.050
201803 0.102 105.300 0.113
201806 0.142 104.900 0.157
201809 -0.065 106.600 -0.071
201812 -0.012 106.500 -0.013
201903 0.047 107.700 0.051
201906 0.011 107.700 0.012
201909 0.026 109.800 0.028
201912 -0.029 111.200 -0.030
202003 -0.052 112.300 -0.054
202006 0.056 110.400 0.059
202009 0.050 111.700 0.052
202012 -0.210 111.500 -0.219
202103 -0.060 112.662 -0.062
202106 0.043 111.769 0.045
202109 0.178 112.215 0.184
202112 0.137 113.108 0.141
202203 -0.040 114.335 -0.041
202206 0.055 114.558 0.056
202209 0.064 115.339 0.065
202212 0.188 115.116 0.190
202303 0.039 115.116 0.039
202306 -0.036 114.558 -0.037
202309 0.121 115.339 0.122
202312 0.147 114.781 0.149
202403 0.227 115.227 0.229
202406 0.101 114.781 0.102
202409 0.013 115.785 0.013
202412 -0.075 114.893 -0.076
202503 0.025 115.116 0.025
202506 0.123 114.907 0.124
202509 0.015 115.471 0.015
202512 0.211 115.832 0.212
202603 0.021 116.303 0.021

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥0.11 mean?
North China Pharmaceutical Co (SHSE:600812) has a Cyclically Adjusted FCF per Share of ¥0.11 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on North China Pharmaceutical Co and its competitors.
Is North China Pharmaceutical Co's Cyclically Adjusted FCF per Share too high?
North China Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥0.11. Overall, North China Pharmaceutical Co has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does North China Pharmaceutical Co's Cyclically Adjusted FCF per Share compare to ZTS?
North China Pharmaceutical Co's Cyclically Adjusted FCF per Share of ¥0.11 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on North China Pharmaceutical Co and its competitors. North China Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is North China Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, North China Pharmaceutical Co (SHSE:600812) is currently considered Fairly Valued. The stock's GF Value™ is ¥4.85, compared to a current price of ¥5.08 — trading 4.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥0.11. North China Pharmaceutical Co's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For North China Pharmaceutical Co (SHSE:600812), the current Cyclically Adjusted FCF per Share is ¥0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is North China Pharmaceutical Co (SHSE:600812) Overvalued in 2026?

Based on GuruFocus' analysis, North China Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.08 is trading 4.7% above its estimated GF Value™ of ¥4.85. GuruFocus considers North China Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600812:

  • Cyclically Adjusted FCF per Share: ¥0.11
  • GF Value™: ¥4.85 vs. price of ¥5.08 (4.7% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600812 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


North China Pharmaceutical Co Business Description

Address No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
52GF Score

Get the complete analysis for SHSE:600812

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.08
Price
¥4.85
GF Value